PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19500885-2 2009 Aromatase inhibition is usually achieved with steroids structurally related to the substrate of catalysis or, alternatively, with azole non-steroid compounds. Azoles 130-135 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 0-9 32046297-5 2020 This theoretical study investigated the active agonist and antagonist properties of "chemical classes of azoles" to determine the relationships of azole interaction with CYP19A1, using stereochemical and electronic properties of the molecules through classification and multilinear regression (MLR) modeling. Azoles 105-111 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 170-177 32046297-5 2020 This theoretical study investigated the active agonist and antagonist properties of "chemical classes of azoles" to determine the relationships of azole interaction with CYP19A1, using stereochemical and electronic properties of the molecules through classification and multilinear regression (MLR) modeling. Azoles 105-110 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 170-177 32046297-10 2020 This study proposes that the electron penetration of azoles toward heme group decides the binding behavior and stereochemistry requirement for antagonist activity against CYP19A1 enzyme. Azoles 53-59 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 171-178 24274332-6 2014 Inhibition of other CYPs, such as aromatase (CYP19), can lead to numerous toxicological effects, which are also evident from high dose human exposures to therapeutic azoles. Azoles 166-172 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 45-50 32435378-0 2020 Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. Azoles 78-83 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 48-57 32435378-5 2020 In this context, here we designed, synthesized, and performed in vitro inhibitory tests on the aromatase enzyme and distinct ER+/ER- BC cell line types of novel azole bridged xanthones. Azoles 161-166 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 95-104 31330226-2 2019 The aim of this study was to mechanistically investigate the endocrine disrupting potential of four commonly used azole antifungal drugs; clotrimazole, miconazole, ketoconazole and fluconazole in vitro using the H295R cell assay and two recombinant, CYP17A1 and CYP19A1 (aromatase), assays. Azoles 114-119 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 262-269 15554355-0 2004 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Azoles 83-89 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 62-67 16330141-0 2006 Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Azoles 29-35 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 20-25 16330141-4 2006 Inhibition of CYP19 (aromatase) is the working principle for tumor therapy, but is an unwanted side effect of azoles used as fungicides or antifungal drugs. Azoles 110-116 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 14-19 16330141-5 2006 The inhibition of recombinant human CYP19 by 21 azoles in use for the three different purposes was investigated using the natural substrate testosterone. Azoles 48-54 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 36-41 15380230-2 2004 Azole derivatives such as letrozole or anastrozole have been developed for aromatase inhibition and are used for the treatment of breast tumors. Azoles 0-5 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 75-84 15554355-2 2004 Antifungal activity is based on inhibition of fungal CYP51 (lanosterol 14alpha-demethylase), and estrogen biosynthesis reduction is due to azole inhibition of CYP19 (aromatase). Azoles 139-144 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 159-164 15554355-4 2004 A fluorimetric assay based on human recombinant CYP19 enzyme with dibenzylfluorescein as a substrate was used to compare the inhibitory potency of 22 azole compounds. Azoles 150-155 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 48-53 35176449-0 2022 Exploration of structural requirements for azole chemicals towards human aromatase CYP19A1 activity: Classification modeling, structure-activity relationships and read-across study. Azoles 43-48 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 83-90 35176449-4 2022 A toxicological evaluation of commonly used azole-based drugs and agrochemicals with respect to CYP19A1is currently requested by the European Union- Registration, Evaluation, Authorization and Restriction of Chemicals (EU-REACH) regulations due to their potential as endocrine disruptors. Azoles 44-49 cytochrome P450 family 19 subfamily A member 1 Homo sapiens 96-103